A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Listed as NCT01424813, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by Teva Branded Pharmaceutical Products R&D, Inc., it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — May 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bethesda, United States , Birmingham, United States , Charleston, United States , Cincinnati, United States , Costa Mesa, United States , Denver, United States , Fairfax, United States , Fountain Valley, United States , Gaithersburg, United States , Huntington Beach, United States and 23 more locations